摘要
目的:对照分析阿戈美拉汀和艾司西酞普兰治疗抑郁症的临床效果及安全性,为临床治疗提供参考。方法:选取四川省南充精神卫生中心2016年6月至2018年6月期间所收治的150例抑郁症患者作为研究对象,随机分为2组,每组75例,对照组予以艾司西酞普兰治疗,研究组予以阿戈美拉汀治疗,治疗前和每个疗程结束后通过汉密尔顿抑郁量表(HAMD)对治疗效果进行评价,并通过不良反应量表(TESS)对药物不良反应(ADR)进行评价。结果:治疗前2组HAMD评分无显著性差异(P>0.05),治疗后2组患者HAMD评分较治疗前均有显著改善(P<0.01);治疗2周末研究组HAMD总评分明显低于对照组(P<0.05),治疗4周及8周末2组患者的HAMD总评分无明显差异(P>0.05);治疗期间,实验组TESS评分显著低于对照组(P<0.05)。结论:阿戈美拉汀治疗抑郁症的总显效率与艾司西酞普兰相当,但阿戈美拉汀起效更快、不良反应少,改善睡眠障碍效果更好,是一种安全、有效的抗抑郁药。
OBJECTIVE To compare and analyze the effectiveness and safety of agomelatine and escitalopram in the treatment of depression,and provide reference for clinical treatment.METHODS A total of 150 patients with depression admitted to Sichuan Nanchong Mental Health Center from June 2016 to June 2018 were selected as study subjects and randomly divided into two groups,75 patients in each group.The control group were treated with escitalopram and the study group were treated with agomelatine.The treatment effect was evaluated by Hamilton Depression Scale(HAMD)before and after each treatment course,and adverse drug reactions(ADRs)were evaluated by adverse reaction scale(TESS).RESULTS Before treatment,there was no significant difference in HAMD scores between the two groups(P>0.05).After treatment,the HAMD score of the two groups was significantly improved compared with that before treatment(P<0.01).At the end of 2 weeks after treatment,the total score of HAMD in the study group was significantly lower than that in the control group(P<0.05).But At the end of 4 weeks and 8 weeks,there was no significant difference between the two groups(P>0.05).During the treatment period,the total score of TESS in the study group was significantly lower than that the control group(P<0.05).CONCLUSION Agomelatine has the same total effective rate as escitalopram in the treatment of depression,but it is a safe and effective antidepressant with faster onset,fewer adverse reactions and better improvement of sleep disturbance.
作者
张德伦
陈林
ZHANG De-lun;CHEN Lin(Pharmacy Department,Nanchong Mental Health Center of Sichuan Province,Sichuan Nanchong 637000,China;Psychosomatic Disease Department,Nanchong Mental Health Center of Sichuan Province,Sichuan Nanchong 637000,China)
出处
《中国医院药学杂志》
CAS
北大核心
2019年第9期966-968,973,共4页
Chinese Journal of Hospital Pharmacy
